Legochem Company ppt

LegoChem Bioscience, Inc.A Leading Chemistry-Based Venture Company

COMPANYOVERVIEW

Contents Company Overview

Business Approach

Project Overview

Summary

Mission Statement

LegoChem Biosciences ( “LCB”) is committed to the discovery and development of novel small-molecule drugs employing faster and more efficient ways by combining LegoChemistry and early ADME/T screening platform technologies.

ABOUT BUSINESS PROJECT SUMMARYABOUT

Corporate Overview Established in May 2006 (Daeduk Science Town, Daejeon, Korea )

Raised 10.3 billion Korean wons (≈ 10 million US$) since its inception

Has built sustainable pipelines in the therapeutic areas of antibiotics, anticoagulants, and oncology

The frontrunner, 2nd generation oxazolidinone antibiotics against MRSA is now in regulatory preclinical studies CRO: MPI in USA

Novel FXa Inhibitor (anticoagulants) is in regulatory preclinical studies jointly with Green Cross, and is licensed out at the candidate stage to Green Cross in June 2009

Experienced and seasoned executive and scientific management team

Preparing IPO to KOSDAQ


Management Team

CEO & President

Director of New Drug R&D , 23 yrs at LGLS Co-Founder of LCB, Ph.D. /Chemistry, KAIST

CTO & Sr. VP

Project Leader, 10 yrs at LGLS Co-Founder of LCB, Ph.D. /Chemistry, MIT

Head of Biology /

VP

Project Leader, 5 yrs at LGLS Co-Founder of LCB, Ph.D. / Microbio, Ohio state

Chemistry Sr. Director

Project Leader at LGLS 18 journal, 5 patent publications Ph.D. / Chemistry, Yonsei U.

CFO / VP

GM, R&D Management, 20 yrs at LGLS Co-Founder of LCB, BS/Economy, Korea Univ

Chemistry Director

Principal Research at LGLS, Ph.D. / Seoul Nation U. 8 journal, 2 patent publications

Biology Director

Research Scientist, 11 yrs at LGLS, 4 journal, 10 patent pub. MS /Biochem, Yonsei U.


Yong Zu Kim, Ph.D

Tae Kyo Park, Ph.D Sung Ho Woo, Ph.D Sejin Park Young Lag Cho, Ph.D Ho Young Song, Ph.D Hyang Suk Lee

Business Strategy and Model

Collaborative R&Dor

Research Services

Sponsored R&D

orCollaborative

R&D

Collaborative R&D

IndependentR&D

Model 1 : Independent R&D

Internal research & development up to phase 2a

License-out at early ~ mid stage (i.e. Oxazolidinone antibiotics, FXa Inhibitor)

Model 2 : Collaborative R&D

Joint research with strong biology platform up to phase IIa

License-out at early ~ mid stage (i.e. Anticancer : HSP90, Mitochondriotropic)

Model 3 : Sponsored R&D

Sponsored R&D cost from partner up to candidate stage

License-out to partner at candidate stage and developed & commercialized by partner (i.e. FVIIa Inhibitor)

RIS

K

CORE COMPETENCY

Biology BasedMed Chem

Based

ABOUT BUSINESS PROJECT SUMMARYBUSINESS

•Medicinal Chemistry• LegoChemistry

•Screening• Early ADMET

◆ Proprietary drug discovery candidates

◆ Early stage L/O

Proprietary Drug Development(chemistry –driven challenge)

◆ Drug discovery and development of candidate

◆ Early~mid stage L/O

Drug development through collaborative research

(Biology-driven challenge)

◆ Customized compound synthesis

◆ Early ADME/T service

Business Research Service

Strategic Alliances

Gate Decision System

Core Technology

Business ModelABOUT BUSINESS PROJECT SUMMARYBUSINESS

Efficacy Focus

In vitro/in vivo efficacy

Selectivity

Metabolic stability

CYP inhibition (DDI)

Protein Binding

Solubility

Stability(plasma, solution)

Safety Focus

Ames

hERG (Patch Clamp)

Single dose Tox

Repeated dose Tox (1W)

3rd GatePre-CandidateConfirmation

Phase I CandidateConfirmation

Lead Preclinical CandidateConfirmation2nd Gate1st Gate

PK/PD Focus In vitro/in vivo efficacy Selectivity Metabolic stability CYP inhibition (DDI) Protein Binding Solubility Stability (plasma, solution) PK (t1/2, Vd, CL, AUC) Cytotoxicity BA(rat) > 20%

Establish 3 level gate systems for preclinical candidates, and define the evaluation criteria based on experience and know-how, to pre-validate and apply failing factors during the post

preclinical development phase

Gate Decision System


Platform Technology: LegoChemistry

“New Lego block” molded into existing best chemical structures

New Pieces of Lego Block

Way of Implementation

1. Previously unknown2. Known but not well-exploredLCB has more than 20 drug-like unique scaffolds

AREA1. Disease area with experience2. Validated (existing) target

METHOD3. Fragment-based approach4. Multi-component reactions5. Replacement of existing subgroup

A

B

C

Time to candidate : 12 ~ 18 months

Successful cases1. FXa inhibitor (LCB02-0133)2. Antibiotics (LCB01-0371)

Derived from same Lego Block


LegoChemistry / Affi. assayCombi-Chem/HTS

기존 Approach 레고켐 Approach

1990 Present

(one by one) (multi by semi-multi) (once and all)

Traditional approach

Manual single synthesis

Singleton Assay

Combi-Chem - Simultaneous synthesis of

various substances / Individual

Separation - druglike lack of verification

HTS - Fixed unit multi-well Assay

LegoChemistry

- Synthesis of various materials

simultaneously without separation - Starts from Druglike scaffold

Affinity Assay

- One conclusive assay for

complete mixture of synthetic

material

Candidate

Discovery Method

3,800 : 1

Over 5 years

5,800 : 1

Average 5 years

R&DProductivity

(Candidate for discovery) ☞ Merck Standard

The synthesis of core competencies

Shortening candidate discovery time from 5 to 3 years by utilizing tools like LegoChemistry

500 : 1 (or less)

Less than 3 years


More than 5 clinical pipelines for new drug by 2012(Benchmarking: Gilead Science)

Initiate pipeline(’06 ~’08)

Grow pipeline(’09 ~’11)

Sustain pipeline (’12 ~ )

2 Preclinical candidates,

1 License-out1 Co-Research

contract

3 Clinical pipeline 2 License-out

1 preclinical study/year

5 Clinical pipeline3 License-out

1 clinical study / year

Collaboration network Global network Global licensing-out

Independent research and development company

Manage the process from discovery to development

Output

CoreCompetencies

Mid-term Business Plan


Research Projects

Project Selection Guideline

Management’s Previous Experience

antibiotics, anticoagulants, anticancer

Attractiveness to big pharm

unmet medical needs

Portfolio Balance (risk management)

best-in-class vs. first-in-class

Projects

Antibiotics

Oxazolidinone antibiotics , MDR-TB

Gram(-) antibiotics

Anticoagulants

FXa inhibitor (Partnered with Green Cross)

FVIIa inhibitor (Partnered with Hanmi)

FXIa inhibitor

Anti-cancer

HSP 90 (Partnered with Boram Pharma) Mitochondriotropic

Others

DDR2 / HIF-1(Wondonin) / CD-99

ABOUT BUSINESS PROJECT SUMMARYPROJECT

Project RoadmapProgram Lead Optimiza-

tion Preclinical Phase 1 Phase 2a

Antibiotics

- Oxazolidinone(LCB01-371)

- Gram(-) antibioticss

- TB

Anticoagulants

- FXa Inhibitor

- FVIIa Inhibitor

- FXIa Inhibitor

Anticancer

- HSP90(Small molo)

- Mitichondriotropic

Others

- DDR2

- HIF1(Wondonin)

(by Green Cross)


Discovery Projects: Summary

Res. Area

Project Current Stage and Future Plan

Anti-biotics

Gram(-) Expecting preclinical candidate at the end of 2010 National Research Fund

TB Several lead compounds selected Expecting preclinical candidate at the end 2010

Anti-coagu-lant

FVIIa Lead optimization stage with 1 PCT filed: Joint research with Hanmi Pharm Pre-candidate expected by the end of 2010

FXIa Lead Optimization Stage Mainly operated by Fragment-based Drug Discovery approach Three novel fragments (~uM) under extensive optimization

Anti-cancer

HSP90 (1)

Joint research with Boram Pharm, Asan Medical Center, Seoul Small molecular approach; candidate soon-to-be selected

HSP90 (2)

Mitochondriotropic agent in Joint Research with Hanmi Pharm Selected as one of LEADER Program: Currently at pre-candidate stage

Others

HIF-1(Won-donin)

Extensive derivatization of natural product known to be a HIF-1 inhibitor Evaluating for ophthalmic therapy with the Catholic Univ. of Ko-rea, School of Medicine

CD-99 Pre-candidate inhibitors in hand: RA, Anticancer, Diabetic Retinopathy Joint Research with Kangwon Univ.

DDR-2 Pre-candidate inhibitors in hand: atopic application planned Joint Research with Korea Institute of Science & Technology


Scope of IP landscape

Antibiotics

FXa inhibitors

FVIIa inhibitors

Anticancer Patent to be published

2006 2007 2008 2009 2010

0

1

2

3

4

Patent Filings

Year

# P

ate

nt

file

d

+

ABOUT BUSINESS PROJECT SUMMARYSUMMARY

Summary of LCB Experienced and skilled researchers

Hands on experience on driving project from early lead discovery to FDA approval

Established experience and network for licensing-out, collaboration, and negotiation with multi-national pharmaceutical companies

Excellence of Core Technology Unique distinction of LegoChemistry scaffold approach

Ability to generate consistent project pipeline ( >20 novel Scaffold, 25,000 compounds focused library)

Systematic research plan via Gate Decision System Established guidelines for key stage decision to distinguish between ‘good’ and ‘bad’

drugs

Implementing ‘fast track’ new drug discovery

Passion for new drug development New drug discovery is the only way to survive!

“Establishing a new drug pipeline is dependent on securing drug-like leads, and LCB has the necessary technology, system and passion to

deliver it.”

Candidate discovery

Preclinical Phase I Phase II Phase III FDA approval

Cases 4 1 4 2 - 1

Project Antiboitics, Dementia, Hyperlipidemia, Hepatitis C

Chemotherapy

HIV, Diabetes, Anticoagulation, Obesity

Hepatitis B, Caspase inhibitor

Quinolone antibiotics (Factive)

ABOUT BUSINESS PROJECT SUMMARYSUMMARY

Contact LegoChem Biosciences, Inc.

Daejeon Bio Venture Town, 461-8 Jeonmin-dong, Yuseong-gu, Daejeon, 305-811, South Korea

http://www.legochembio.com/

CONTACT: Sung-Ho Woo, Ph.D. Biology Director & Senior VP [Tel] +82-42-861-0688

[Fax] +82-42-861-0689

E-mail: [email protected]

Request for more materials ONE PAGE: Brief outline of a project in a one page PDF file

PROJECT PPT: Detailed version of a project description and a 5 MIN VIDEO presentation

COMPANY DOC: Comprehensive overview of company’s business plan and project description in written format.